This article was originally published in Start Up
CardioPhotonics' HeartLight monitors fluid volumes in real time and is normalized to patients during surgery. The company believes that the ability to accurately assess the patient’s condition and consequently avoid the over- or underadministration of fluids will reduce post-surgical complications that can prolong hospital stay and increase health care costs.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. "As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors," features profiles of Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharmaceuticals. Plus these Start-Ups Across Health Care: CardioPhotonics, Eureka Genomics, Invuity and OrthoSensor.
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.